Trial reportBritish journal of cancer2003
Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
Trial report in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00290485 (A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Liver resection for metastatic GIST tumor improves survival in the era of tyrosine kinase inhibitors: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2023Pooled it
- Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.Journal of Korean medical science · 2010Guideline
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.Journal of surgical oncology · 2009Trial
- Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- TUFM-knockdown inhibits the migration and proliferation of gastrointestinal stromal tumor cells.Oncology letters · 2020Article
- Enormous gastrointestinal stromal tumor arising from the stomach causing weight loss and anemia in an elderly female: Case report.International journal of surgery case reports · 2019Article
- Gastrointestinal stromal tumours: advances in surgical and pharmacological management options.Journal of gastrointestinal oncology · 2018Review
- Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor.Cancer research and treatment · 2016Article
- Rare cystic liver lesions: a diagnostic and managing challenge.World journal of gastroenterology · 2013Review
- Fool's gold, lost treasures, and the randomized clinical trial.BMC cancer · 2013Article
- Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case.Surgery today · 2012Article
- Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea.Cancer research and treatment · 2012Article
- Updates on the management of gastrointestinal stromal tumors.Surgical oncology clinics of North America · 2012Article
- KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients.PloS one · 2012Article
- Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.International journal of cancer · 2011Review
- Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor.Journal of the Korean Society of Coloproctology · 2011Article
- Gastrointestinal stromal tumors (GISTs): an updated experience.Digestive diseases and sciences · 2010Review
- Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.World journal of surgery · 2010Article
- Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors.Medical oncology (Northwood, London, England) · 2010Article
- NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Journal of the National Comprehensive Cancer Network : JNCCN · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant gastrointestinal stromal tumours (GIST) have a poor prognosis. Since these tumours are resistant to conventional radiation and chemotherapy, surgery has been the mainstay of treatment. However, surgery is usually inadequate for the treatment of malignant GIST. Imatinib, a KIT tyrosine kinase inhibitor, has recently been found to have a dramatic antitumour effect on GIST. In this centre-based study of 17 consecutive patients with high-risk or overtly malignant GIST, imatinib was used in three different settings - palliatively, adjuvantly, and neoadjuvantly. The treatment was found to be safe and particularly effective in tumours with activating mutations of exon 11 of the KIT gene. Clinical response to imatinib treatment correlated morphologically to tumour necrosis, hyalinisation, and reduced proliferative activity. The value of neoadjuvant imatinib treatment was illustrated in one case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.